乙基(1S,2R,3S,4S,5S)-2,3-O-(异亚丙基)-4-羟基双环[3.1.0]己烷羧酸酯 | 793695-59-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 乙基(1S,2R,3S,4S,5S)-2,3-O-(异亚丙基)-4-羟基双环[3.1.0]己烷羧酸酯
• 英文名称: ethyl (1S,2R,3S,4S,5S)-2,3-O-(isopropylidene)-4-hydroxybicyclo[3.1.0]hexanecarboxylate
• 英文别名: ethyl (1S,2R,3S,4S,5S)-2,3-O-isopropylidene-4-hydroxybicyclo[3.1.0]hexane-1-carboxylate；Ethyl (1R,2S,4S,5S,6S)-5-hydroxy-8,8-dimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonane-2-carboxylate
• CAS: 793695-59-7
• 化学式: C₁₂H₁₈O₅
• 分子量: 242.272
• InChiKey: SBJHJYQWYJORMZ-FJVRFIPSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  乙基(1S,2R,3S,4S,5S)-2,3-O-(异亚丙基)-4-羟基双环[3.1.0]己烷羧酸酯 在 偶氮二甲酸二异丙酯 、 三乙胺 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 (1R,2S,4S,5R,6S)-5-[6-[(3-bromophenyl)methylamino]-2-chloropurin-9-yl]-N,8,8-trimethyl-7,9-dioxatricyclo[4.3.0.02,4]nonane-2-carboxamide
  参考文献：
  名称：

  (N)-Methanocarba 2,N⁶-Disubstituted Adenine Nucleosides as Highly Potent and Selective A₃ Adenosine Receptor Agonists

  摘要：

  A series of ring-constrained (N)-methanocarba-5 '-uronamide 2,N-6-disubstituted adenine nucleosides have been synthesized via Mitsunobu condensation of the nucleobase precursor with a pseudosugar ring containing a 5 '-ester functionality. Following appropriate functionalization of the adenine ring, the ester group was converted to the 5 '-N-methylamide. The compounds, mainly 2-chloro-substituted derivatives, were tested in both binding and functional assays at human adenosine receptors (ARs), and many were found to be highly potent and selective A(3)AR agonists. Selected compounds were compared in binding to the rat A(3)AR to assess their viability for testing in rat disease models. The N-6-(3-chlorobenzyl) and N-6-(3-bromobenzyl) analogues displayed K-i values at the human A(3)AR of 0.29 and 0.38 nM, respectively. Other subnanomolar affinities were observed for the following N-6 derivatives: 2,5-dichlorobenzyl, 5-iodo-2-methoxybenzyl, trans-2-phenyl-1-cyclopropyl, and 2,2-diphenylethyl. Selectivity for the human A3AR in comparison to the A(3)AR was the following (fold): the N-6-(2,2-diphenylethyl) analogue 34 (1900), the N-6-(2,5-dimethoxybenzyl) analogue 26 (1200), the N-6-(2,5-dichlorobenzyl) and N-6-(2-phenyl-1-cyclopropyl) analogues 20 and 33 (1000), and the N-6-(3-substituted benzyl) analogues 17, 18, 28, and 29 (700-900). Typically, even greater selectivity ratios were obtained in comparison with the A(2A) and A(2B)ARs. The (N)-methanocarba-5 '-uronamide analogues were full agonists at the A(3)AR, as indicated by the inhibition of forskolin-stimluated adenylate cyclase at a concentration of 10 mu M. The N-6-(2,2-diphenylethyl) derivative was an A(3)AR agonist in the (N)-methanocarba-5 '-uronamide series, although it was an antagonist in the ribose series. Thus, many of the previously known groups that enhance A(3)AR affinity in the 9-riboside series, including those that reduce intrinsic efficacy, may be adapted to the (N)-methanocarba nucleoside series of full agonists.

  DOI：

  10.1021/jm049580r
• 作为产物：
  描述：

  (1R)-1-((4R,5S)-2,2-dimethyl-5-vinyl[1,3]dioxolan-4-yl)ethane-1,2-diol 在 甲醇 、 sodium tetrahydroborate 、 sodium periodate 、 copper(l) iodide 、 对甲苯磺酰叠氮 、 对甲苯磺酸 、 三乙胺 、 tin(ll) chloride 作用下， 以 二氯甲烷 、 水 、 丙酮 、 甲苯 、 乙腈 为溶剂， 反应 25.0h， 生成 乙基(1S,2R,3S,4S,5S)-2,3-O-(异亚丙基)-4-羟基双环[3.1.0]己烷羧酸酯
  参考文献：
  名称：

  [EN] COMPOUNDS TARGETING PRMT5
  [FR] COMPOSÉS CIBLANT PRMT5

  摘要：

  本文提供了式（I）的化合物或其药用盐，包括含有本文描述的化合物（包括本文描述的化合物的药用盐）的药物组合物以及合成这些化合物的方法。本文还提供了使用式（I）的化合物或其药用盐治疗疾病和/或症状的方法。

  公开号：

  WO2020205867A1

文献信息

• Molecular recognition in the P2Y14 receptor: Probing the structurally permissive terminal sugar moiety of uridine-5′-diphosphoglucose
  作者：Hyojin Ko、Arijit Das、Rhonda L. Carter、Ingrid P. Fricks、Yixing Zhou、Andrei A. Ivanov、Artem Melman、Bhalchandra V. Joshi、Pavol Kováč、Jan Hajduch、Kenneth L. Kirk、T. Kendall Harden、Kenneth A. Jacobson

  DOI：10.1016/j.bmc.2009.05.024

  日期：2009.7

  substitution by chain extension through an amide linkage. Functionalized congeners containing terminal 2-acylaminoethylamides prepared by this strategy retained P2Y14 activity, and molecular modeling predicted close proximity of this chain to the second extracellular loop of the receptor. In addition, replacement of glucose with other sugars did not diminish P2Y14 potency. For example, the [5′′]ribose derivative

  P2Y 14受体是一种核苷酸信号蛋白，由尿苷-5'-二磷酸葡萄糖1和其他尿嘧啶核苷酸激活。我们已经确定1的葡萄糖部分是设计该 P2Y 14激动剂类似物的最结构允许区域。例如，尿苷-5'-二磷酸葡萄糖醛酸的羧酸酯基团被证明适用于通过酰胺键进行链延伸的灵活取代。通过该策略制备的含有末端 2-酰基氨基乙基酰胺的功能化同源物保留了 P2Y 14活性，分子模型预测该链与受体的第二个细胞外环非常接近。此外，用其他糖替代葡萄糖不会降低 P2Y 14效力。例如，[5'']核糖衍生物的EC 50为0.24 μM。的葡萄糖部分的选择性monofluorination指示用于2'角色' -和6'' -的羟基1受体识别。β-葡萄糖苷的效力比天然 α-异构体低两倍，但 1''-氧的亚甲基替代消除了活性。用环戊基或刚性双环 [3.1.0] 己烷基团取代核糖环系统消除了活性。Uridine-5'-diphosphoglucose
• [EN] PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS<br/>[FR] DERIVES DE PURINE COMME AGONISTES DU RECEPTEUR D'ADENOSINE A3 ET A1
  申请人：US GOV HEALTH & HUMAN SERV

  公开号：WO2006031505A1

  公开（公告）日：2006-03-23

  Disclosed are (N)-methanocarba adenine nucleosides of the formula: [Formula] as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias. The invention also provides compounds that are agonists of both A1 and A3 adenosine receptors for use in cardioprotection.

  揭示了一种公式为[N-甲烷卡巴腺嘌呤核苷]的高效A3腺苷受体激动剂，包括这种核苷的制药组合物，以及这些核苷的使用方法，其中R1-R6如规范中所定义。这些核苷被考虑用于治疗多种疾病，例如炎症、心肌缺血、中风、哮喘、糖尿病和心律失常。该发明还提供了既是A1受体又是A3受体激动剂的化合物，用于心脏保护。
• A New Synthetic Route to (North)-Methanocarba Nucleosides Designed as A₃ Adenosine Receptor Agonists
  作者：Bhalchandra V. Joshi、Hyung Ryong Moon、James C. Fettinger、Victor E. Marquez、Kenneth A. Jacobson

  DOI：10.1021/jo0487606

  日期：2005.1.1

  (N)-methanocarba nucleosides, such as MRS1898 and MRS2346, are examples of full agonists of the human A3 AR. An improved convergent approach from easily accessible 2,3-O-isopropylidene-d-erythrose (2b), and the combination of a strategic intramolecular cyclopropanation step plus the acid-catalyzed isomerization of an isopropylidene group, provided a suitable pseudosugar precursor (23) for the synthesis of MRS1898

  A 3腺苷受体（AR）的激活与脑保护，心脏保护和抗癌作用有关。在有效的和选择性的A 3 AR激动剂中，有新颖的甲氨基碳腺苷类似物，其中伪核糖部分的构象被锁定在伪旋转周期的北半球。5'-尿酰胺（N）-甲氨基甲酸核苷，例如MRS1898和MRS2346，是人A 3 AR完全激动剂的实例。从容易获得2,3-一种改进的会聚途径ö异亚丙基d -erythrose（2b中），以及策略性的分子内环丙烷化步骤与异亚丙基的酸催化异构化相结合，为合成MRS1898，MRS2346和相关类似物提供了合适的假糖前体（23）。这种新的合成路线使用了容易获得的构建基块，并为以合理规模准备各种目标开辟了道路。
• Scaffold Repurposing of Nucleosides (Adenosine Receptor Agonists): Enhanced Activity at the Human Dopamine and Norepinephrine Sodium Symporters
  作者：Dilip K. Tosh、Aaron Janowsky、Amy J. Eshleman、Eugene Warnick、Zhan-Guo Gao、Zhoumou Chen、Elizabeth Gizewski、John A. Auchampach、Daniela Salvemini、Kenneth A. Jacobson

  DOI：10.1021/acs.jmedchem.7b00141

  日期：2017.4.13

  At DAT, the binding of two structurally dissimilar radioligands was enhanced; NET binding of only one radioligand was enhanced; SERT radioligand binding was minimally affected. 10 was more potent than cocaine at inhibiting DA uptake (IC50 = 107 nM). Ribose analogues were weaker in DAT interaction than the corresponding bicyclics. Thus, we enhanced the neurotransmitter transporter activity of rigid nucleosides

  我们重新调整了 (N)-methanocarba 腺苷衍生物（A3 腺苷受体 (AR) 激动剂）的用途，以增强放射性配体在人多巴胺 (DA) 转运蛋白 (DAT) 上的变构结合并抑制 DA 摄取。我们通过小N6-烷基取代、5'-酯、腺嘌呤的脱氮修饰以及恢复核糖代替甲烷碳，扩展了该系列的结构-活性关系。 C2-(5-卤代-2-基)-乙炔基 5'-甲基 9 (MRS7292) 和 5'-乙基 10 (MRS7232) 酯增强 DAT (EC50 ∼ 35 nM) 和去甲肾上腺素转运蛋白 (NET) 的结合。与 A3AR 相比，9 和 10 在小鼠中对 DAT 具有选择性，但在人类中则不然。在 DAT 中，两种结构不同的放射性配体的结合得到增强；仅一种放射性配体的 NET 结合得到增强； SERT 放射性配体结合受到的影响最小。 10 在抑制 DA 摄取方面比可卡因更有效 (IC50 = 107
• Purine (<i>N</i>)-Methanocarba Nucleoside Derivatives Lacking an Exocyclic Amine as Selective A₃ Adenosine Receptor Agonists
  作者：Dilip K. Tosh、Antonella Ciancetta、Eugene Warnick、Robert O’Connor、Zhoumou Chen、Elizabeth Gizewski、Steven Crane、Zhan-Guo Gao、John A. Auchampach、Daniela Salvemini、Kenneth A. Jacobson

  DOI：10.1021/acs.jmedchem.5b01998

  日期：2016.4.14

  C6-Me and C6-styryl derivatives had unexpectedly high A3AR affinity, other rigid nucleoside analogues lacking an exocyclic amine were prepared. Of these, the C6-Me-(2-phenylethynyl) and C2-(5-chlorothienylethynyl) analogues were particularly potent, with human A3AR Ki values of 6 and 42 nM, respectively. Additionally, the C2-(5-chlorothienyl)-6-H analogue was potent and selective at A3AR (MRS7220, Ki

  缺乏环外胺的嘌呤（N）-甲氨基甲酰基5'-N-烷基尿嘧啶核苷A3腺苷受体（A3AR）激动剂是Sonogashira偶联过程中发生意外反应并随后发生氨解的结果。由于初始的C6-Me和C6-苯乙烯基衍生物具有出乎意料的高A3AR亲和力，因此制备了缺少环外胺的其他刚性核苷类似物。其中，C6-Me-（2-苯基乙炔基）和C2-（5-氯噻吩基乙炔基）类似物特别有效，人A3AR Ki值分别为6和42 nM。此外，C2-（5-氯噻吩基）-6-H类似物在A3AR（MRS7220，Ki 60 nM）处具有强效和选择性，并且还可以完全逆转小鼠坐骨神经机械性异常性疼痛（体内3μmol/ kg，口服）。可以通过同源建模和这些超修饰核苷的对接来合理化缺乏C6 H键供体，同时保持A3AR亲和力和功效。该模型表明，稳定特征的适当组合可以部分弥补环外胺的缺乏，而环外胺是在A3AR结合位点识别的其他重要因素。